Infectious Disease Unit II, Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco, Milano, Italy.
Department of Pathophysiology and Transplantation, University of Milano, Italy.
New Microbiol. 2023 May;46(2):120-132.
Drug-resistant tuberculosis (DR-TB) is a major global health challenge. In 2021, about one third of DR-TB patients worldwide were enrolled in treatment. In order to reach the targets set during by the 2018 UN General Assembly (UNGA) Political Declaration on Tuberculosis, a global effort must be made by both high- and low-incidence countries. Data concerning high-incidence countries are vast in the literature, but insufficient political attention has been paid in low-incidence countries to face this infectious threat. This review aims at providing an overview of DR-TB focused on different facets of DR-TB management. First, global and Italian data on the main at-risk populations for TB and DR-TB were gathered, together with the latest studies on the correlation between TB risk factors and the onset of drug resistance. Second, this review provides an analysis of obsolete Italian guidelines on the diagnosis and management of TB and DR-TB, highlighting the challenges that our country is currently facing to properly implement the latest international recommendations. Finally, some key suggestions are provided to design public health (PH) policies that can effectively tackle the DR-TB issue from a "global health" perspective.
耐多药结核病(DR-TB)是一个重大的全球健康挑战。2021 年,全球约有三分之一的耐多药结核病患者接受了治疗。为了实现 2018 年联合国大会(UNGA)结核病问题政治宣言中设定的目标,高、低发病国家都必须做出全球努力。文献中有大量关于高发病国家的数据,但在低发病国家,对这一传染性威胁的政治关注不足。本综述旨在概述耐多药结核病,重点关注耐多药结核病管理的不同方面。首先,收集了全球和意大利关于结核病和耐多药结核病主要高危人群的数据,以及结核病风险因素与耐药性发生之间相关性的最新研究。其次,本文分析了意大利关于结核病和耐多药结核病诊断和管理的过时指南,强调了我国目前在正确实施最新国际建议方面面临的挑战。最后,提出了一些关键建议,以制定公共卫生(PH)政策,从“全球健康”的角度有效解决耐多药结核病问题。